Metachromatic LeukodystroPharmaceuticaly Treatment Market Overview and Regional Outlook Study

Metachromatic leukodystrophy is a rare hereditary (genetic) disorder that causes accumulation of fatty substances (lipids) to build up in cells, particularly in the brain, spinal cord, and peripheral nerves. This buildup is caused by a deficiency of an enzyme called sulfatides that helps break down lipids.
The brain and nervous system progressively lose function because the substance that covers and protects the nerve cells (myelin) is damaged
Metachromatic leukodystrophy is of three types: Late Infantile Form, Juvenile Form, and Adult Form
This causes damage to the protective myelin covering the nerves, resulting in progressive worsening of brain and nervous system functions
Treatment options include pipeline products which can cure only symptoms of disease. These products can produce effects such as prevention of nerve damage, slowing progression of the disorder, preventing complications, and providing supportive care.

Request a Sample to Get Extensive Insights into the Metachromatic Leukodystrophy Treatment Market

Increase in clinical trials with potential treatment options in coming years and increase in diagnosed cases are some of the major factors responsible for the growth of global metachromatic leukodystrophy market
For instance, in 2019, Takeda Pharmaceutical Company Limited successfully initiated the phase II study of an Intrathecal SHP611 in participants with Late Infantile Metachromatic Leukodystrophy
Rise in awareness about rare diseases in developed as well as developing regions is also expected to fuel the growth of global metachromatic leukodystrophy treatment market
Moreover, development of novel drug molecules for the symptomatic relief of metachromatic leukodystrophy is expected to contribute toward the growth of global metachromatic leukodystrophy treatment market in the next few years

Not a single approved pharmacological product is available in the market for complete cure of metachromatic leukodystrophy which can hamper the market growth
Higher cost of stem cell transplantation in some developing countries can also inversely impact the market growth

Based on treatment type, the global metachromatic leukodystrophy treatment market can be segmented into pharmacotherapy and stem cell transplantation
Stem cell transplantation accounted for major market share in 2019 as it is the only approved treatment option currently in the market
Pharmacotherapy is expected to dominate the global market with higher CAGR during the forecast period due to several pipeline products which are expected to launch in coming years and novel mechanism of action for treatment
Pharmacotherapy can be further divided into gene therapy, direct enzyme replacement, oligodendroglial cell therapy, and others

Looking for Customized Insights to build your Business for Future, Ask for a Custom Report here

In terms of sales channel, the global metachromatic leukodystrophy treatment market can be divided into hospitals, clinics, retail pharmacies, and others
Hospitals segment dominated the global market in 2019 due to growing admission of patients for stem cell transplantation and availability of well-equipped staff